Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Status: | Active, not recruiting |
---|---|
Conditions: | Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any - 30 |
Updated: | 3/31/2019 |
Start Date: | September 2006 |
End Date: | September 2021 |
The main purpose of this study is to assess the short term and the long term side effects of
proton beam radiation for pediatric bone and non-rhabdomyosarcoma soft tissue sarcomas.
proton beam radiation for pediatric bone and non-rhabdomyosarcoma soft tissue sarcomas.
- Participants will receive radiation treatments once per day, 5 days a week for a total
of 4 to 6 weeks, depending on how much total dose the tumor requires. The radiation
doctor will see the participant once each week to monitor and record any side effects
they may have from radiation treatment.
- A special device will be made for each participant to help them hold still during the
treatment. This may either be a mask or foam cradle, depending on the area to be
treated.
of 4 to 6 weeks, depending on how much total dose the tumor requires. The radiation
doctor will see the participant once each week to monitor and record any side effects
they may have from radiation treatment.
- A special device will be made for each participant to help them hold still during the
treatment. This may either be a mask or foam cradle, depending on the area to be
treated.
Inclusion Criteria:
- Biopsy proven NRSTS or bone sarcoma
- Less than or equal to 30 years of age
- Patients must have been treated with a standardly accepted chemotherapy regimen if
chemotherapy is indicated
- Patients must be willing to receive follow-up care for a minimum of five years after
treatment at MGH and annual visits unless it is too difficult to return to MGH for
follow-up care. In that event, the patient or guardian must be willing to have their
outside medical information released in order to track the results of treatment
- They or their legal guardian must give their informed consent
- Timing of radiation may be according to concurrent protocol
Exclusion Criteria:
- Co-morbidities that would make the use of radiation too toxic to deliver safely, such
as serious local injury of collagen vascular disease
- Patients who are pregnant
- Previous treatment with radiation therapy
- Concurrent adriamycin or gemcitabine chemotherapy is planned, unless on a concurrent
protocol
We found this trial at
2
sites
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Karen Marcus, MD
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Torunn Yock, MD
Click here to add this to my saved trials